Ildong Pharmaceutical Participates in ‘CPhI Worldwide 2024,’ Aiming to Expand Global Markets and Diversify Business

• Exploring Export Opportunities for Cardiovascular Combination Drugs, Oncology and Antibiotics, and CMO Partnerships
• Highlighting Diabetes and Obesity Drug ‘GLP-1’ and Peptic Ulcer Treatment ‘P-CAB’

Ildong Pharmaceutical(CEO Woongsup Yun), participated in CPhI Worldwide 2024, promoting its active pharmaceutical ingredients (APIs), finished drugs, novel drug candidates, core technologies, and manufacturing infrastructure while seeking new business opportunities.

CPhI Worldwide, the largest pharmaceutical and biotech industry exhibition, took place from October 8 to 10 in Milan, Italy.

Ildong set up an exhibition booth in the Korea Pavilion to showcase its offerings and conducted numerous partnering meetings with companies to explore business development and collaboration opportunities.

The company presented its global business portfolio, including combination drugs (Fixed Dose Combination) like Telostop, Twotops, and Droptop, which are already being exported to Southeast Asia, as well as oncology drugs, antibiotics, and wound care dressings such as Meditouch.

Ildong also emphasized its capabilities in contract manufacturing (CMO) using its GMP-certified facilities dedicated to antibiotics and oncology drugs. Furthermore, it sought to establish partnerships for the commercialization of its proprietary drug candidates.

Ildong Pharmaceutical has a robust pipeline in areas such as:

• Metabolic Disorders
• Gastrointestinal Diseases
• Degenerative Diseases

Ongoing efforts include clinical development and commercialization of promising drug candidates.

During the event, the company garnered particular interest in:

1. ID110521156, an oral synthetic drug candidate targeting GLP-1 (Glucagon-Like Peptide-1) receptors for diabetes and obesity.
2. ID120040002, a peptic ulcer treatment from the P-CAB (Potassium-Competitive Acid Blocker) class.
3. ID119040338, a Parkinson’s disease treatment acting as a dual antagonist of adenosine A1 and A2A receptors.
4. ID119031166, a candidate for the treatment of metabolic-associated steatohepatitis (MASH).

Ildong representative stated, “We aim to expand our business into broader healthcare fields, including functional foods and cosmetics, in addition to our existing pharmaceutical products. Furthermore, we plan to diversify our global strategy through new drug pipeline collaborations, licensing-out opportunities, and CMO projects.”